REG-Arix Bioscience PLC Notice of Investor Presentation

Arix BioscienceAnnouncement

22/06/2022 07:15

============

Arix Bioscience PLC (ARIX)
Notice of Investor Presentation

22-Jun-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

═════════════════════════════════════════════════════════════════════════════════

 

                               Arix Bioscience plc

                                         

                         Notice of Investor Presentation

 

LONDON, 22 June 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE:  ARIX),
announces that  CEO, Robert  Lyne,  and Managing  Director,  Mark Chin,  will  be
hosting a live  presentation and Q&A  session via the  online platform,  Investor
Meet Company, at 1:00 p.m. BST on Wednesday 29 June 2022.

 

The presentation is open  to all existing  and potential shareholders.  Questions
can be submitted  pre-event via the  'Investor Meet Company'  dashboard up  until
9:00  a.m.  on  Tuesday   28  June  2022   or  at  any   time  during  the   live
presentation. Investors  can  sign   up  to  Investor   Meet  Company  for   free
via:  1 https://www.investormeetcompany.com/arix-bioscience-plc/register-investor

 

Investors who already  follow Arix  on the  Investor Meet  Company platform  will
automatically receive an invitation to the event.

 

                                      ENDS 

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir 2 @arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

 3 arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global  venture capital company focused on investing  in
breakthrough  biotechnology  companies  around  cutting-edge  advances  in   life
sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise,
and global networks to help accelerate their ideas into important new  treatments
for patients. As  a listed company,  we are  able to bring  this exciting  growth
phase of our industry to a broader range of investors.  4 www.arixbioscience.com

 

 

═════════════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  MSCL
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   169801
   EQS News ID:    1380689


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    5 fncls.ssp?fn=show_t_gif&application_id=1380689&application_name=news&site_id=refinitiv2

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=4d118b3300aa96332de7879ede8cb917&application_id=1380689&site_id=refinitiv2&application_name=news
   2. mailto:charlotte@arixbioscience.com
   3. mailto:arix@powerscourt-group.com
   4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1380689&site_id=refinitiv2&application_name=news


============